argenx NV ADR (ARGX)vsVerizon Communications Inc (VZ)
ARGX
argenx NV ADR
$806.46
-1.20%
HEALTHCARE · Cap: $50.40B
VZ
Verizon Communications Inc
$48.35
-0.42%
COMMUNICATION SERVICES · Cap: $197.15B
Smart Verdict
WallStSmart Research — data-driven comparison
Verizon Communications Inc generates 2834% more annual revenue ($139.15B vs $4.74B). ARGX leads profitability with a 31.4% profit margin vs 12.5%. VZ appears more attractively valued with a PEG of 0.89. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
VZ
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+62.4%
Fair Value
$2217.64
Current Price
$806.46
$1411.18 discount
Margin of Safety
-31.3%
Fair Value
$36.74
Current Price
$48.35
$11.61 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 30.0%
Revenue surging 62.6% year-over-year
Earnings expanding 114.0% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Attractively priced relative to earnings
Large-cap with strong market position
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 25.2%
Generating 3.8B in free cash flow
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 170.5x book value
2.9% revenue growth
4.3% earnings growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 31.4% and operating margin at 30.0%. Revenue growth of 62.6% demonstrates continued momentum.
Bull Case : VZ
The strongest argument for VZ centers on P/E Ratio, Market Cap, PEG Ratio. PEG of 0.89 suggests the stock is reasonably priced for its growth.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : VZ
The primary concerns for VZ are Revenue Growth, EPS Growth, Debt/Equity. Debt-to-equity of 1.90 is elevated, increasing financial risk.
Key Dynamics to Monitor
ARGX profiles as a growth stock while VZ is a value play — different risk/reward profiles.
VZ carries more volatility with a beta of 0.22 — expect wider price swings.
ARGX is growing revenue faster at 62.6% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (73/100 vs 68/100), backed by strong 31.4% margins and 62.6% revenue growth. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Verizon Communications Inc
COMMUNICATION SERVICES · TELECOM SERVICES · USA
Verizon Communications Inc. is an American multinational telecommunications conglomerate and a corporate component of the Dow Jones Industrial Average. The company is headquartered at 1095 Avenue of the Americas in Midtown Manhattan, New York City, but is incorporated in Delaware.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?